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ABSTRACT
Objective: The present study investigated the effects
of switching to different products of the same off-
patent active substance (brand name or generic) on
therapy discontinuation or substitution with another
molecule of the same class, in patients with
cardiovascular disease treated with statins and
antihypertensives in a ‘real-world’ setting.
Design: A retrospective cohort study in a ‘real-world’
setting.
Setting: Analysis of data performed by integrating
administrative databases that included approximately
two million individuals who are assisted by the
National Health System from three Local Health Units
located in three different regions of Italy.
Participants: All patients aged ≥18 years with at least
one prescription of simvastatin, ramipril or amlodipine
in the period 1 January to 31 December 2010 were
included and followed up for 2 years.
Main outcome measures: Prescription refills
occurring during follow-up were evaluated. Frequency
of discontinuation of therapy or substitution with
another molecule of the same class (eg, from
simvastatin to a different statin) during follow-up was
identified.
Results: During follow-up, therapy discontinuation or
substitution was found to be more frequent in patients
switching to a different product of the same active
substance compared with non-switching patients
(11.5% vs 10.8% and 22.2% vs 20.8% (p=0.002),
respectively, in the simvastatin group; 4.0% vs 3.5%
and 24.6% vs 22.7% (p<0.001), respectively, in the
amlodipine group). In the ramipril group, 8% of
patients undertook a therapy substitution to another
molecule; no trend towards a lower percentage of
substitution was observed in the non-switching group,
while 18% of patients discontinued treatment, with a
significant difference in favour of patients not
switching. These findings were partially confirmed by
multivariate analysis.
Conclusions: Switches among products of the same
active substance are quite common in patients with
cardiovascular disease. Our study suggests that
switching may expose patients to a higher risk of
therapy discontinuation or substitution.
INTRODUCTION
Cardiovascular diseases (CVD) are the leading
cause of death worldwide, accounting for
approximately one-third of all deaths.1
Combination therapy with antihypertensive
drugs and serum cholesterol-lowering drugs is
effective in prevention, and it is estimated that
a high level of adherence to treatment will
reduce the risk of CVD by approximately
80%.2 A number of studies have demonstrated
that patients often discontinue long-term
treatment or take less than prescribed, and
that such non-adherence reduces the potential
preventive beneﬁts.3
Strengths and limitations of this study
▪ This study, in a ‘real-world’ setting, is one of
only a few studies to investigate clinical differ-
ences related to switching among different pro-
ducts of the same active substance in the
cardiovascular setting. Until now, most research
has focused only on comparing brand name and
generic drugs.
▪ The sample size was relatively limited, and
although we used three healthcare databases
comprising a total of approximately two million
individuals who are assisted by the National
Health System in three regions of Italy, larger
studies are needed to confirm and to enhance
the generalisability of the findings, and in differ-
ent populations.
▪ In common with other retrospective, observa-
tional studies, reasons for switch, non-adherence
or discontinuation of treatment were not retriev-
able from the data set.
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Many reasons contribute to patient non-adherence to
medical therapy, such as ageing, comorbidities, poor
relationship between patient and physician, poor
memory and patients’ low perception of disease sever-
ity.4 In addition, the need to take several drugs concomi-
tantly or other medication-related factors, may make
remembering when to take each drug more difﬁcult and
increase the risk of possible side effects caused by
adverse drug–drug interactions. Although medication
side effects are probably not the main cause of poor
adherence, as there seems to be little direct relationship
between adherence and drug class,3 they are also asso-
ciated with treatment discontinuation, especially in the
early treatment of hypertension.5–8 Kronish et al showed
that, in the clinical setting, adherence to diuretics and
β-blockers is lowest and the highest adherence is to
angiotensin II receptor blockers and ACE inhibitors.5
Similarly, a retrospective study based on a cohort of
207 473 patients in Ontario found that treatment with
ACE inhibitors showed the best therapy persistence and
compliance, and β-blockers showed the worst compli-
ance (all p<0.001).8 Furthermore, some studies have
demonstrated that switching between different products
of the same active substance can have an impact on
adherence to medication, because variation in pack-
aging and pill appearance may reduce adherence, espe-
cially for chronic diseases.9 10
There is a perception among patients and physicians
alike that frequent changes between branded and
unbranded products (as well as between generics), all
containing the same active substance, and especially if
patients are older and on multidrug regimens, may
cause patients to become anxious when the appearance
of their drugs changes.11–13 This can lead to an
increased risk of patients making mistakes or double
medicating, which ﬂows on to increased drug
non-adherence.14 15
Few studies have investigated clinical differences
related to switching among different products of the
same active substance in the cardiovascular setting. Until
now, most research has focused only on comparing
brand name and generic drugs.16–20
The aim of this study was to investigate the effects of
switching to different products of the same off-patent
active substance (brand name or generic) on therapy
discontinuation or substitution with another molecule of
the same class, in patients with CVD treated with statins
and antihypertensives in a ‘real-world’ setting.
A version of this article has previously been published
as a journal supplement in the Italian language.21
METHODS
Data collection
The data used for the analysis were obtained from the
administrative databases of three local health units
(LHUs), whose databases included a total population of
about two million individuals who are assisted by the
National Health System, in the Italian regions of
Lombardy, Lazio and Campania. We analysed the follow-
ing archives: Assisted Subjects’ Database, containing the
personal data of patients; Medication Prescription data-
base, containing all the information relating to individual
prescriptions dispensed by the pharmacy, such as the
International Nonproprietary Names (INN) for pharma-
ceutical substances, the Anatomical-Therapeutic-Chemical
(ATC) code of the prescribed drug, the number of
packages, the number of units per package, the dose, the
brand name drug, the cost per unit and the date of the
prescription; Hospital Discharge Database (SDO), con-
taining information on each hospital discharge, in particu-
lar the date of admission and discharge, primary and
secondary diagnoses coded according to the International
Classiﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation (ICD-9-CM). The patient code in each data-
base allowed electronic linking among all databases. To
guarantee patient privacy, this patient code was transcoded
into an anonymous univocal numeric code. No identiﬁers
related to patients were provided to the researchers.
According to the Italian law for conﬁdentiality of data,22
the study was notiﬁed to the Ethic Committees of each
LHU.
Cohort definition
The study was a retrospective cohort study including all
patients aged ≥18 years that, between 1 January and 31
December 2010 (enrolment period), had at least one
prescription of simvastatin (ATC code: C10AA01), rami-
pril (ATC code: C09AA05) or amlodipine (ATC code:
C08CA01) as a brand name or generic prescription. The
date of enrolment was deﬁned as the earliest date within
the enrolment period in which the patient had the last
switch of medication or the last prescription in the case
of a patient continuing with the same medication.
Starting from this date, the individual patient was fol-
lowed for 2 years (follow-up period). The patient
cohorts were deﬁned in the following way: non-switchers
were deﬁned as those patients who did not change
medication, regardless of whether it was brand name or
generic; switchers were deﬁned as those patients who
switched among different products of the same off-
patent active substance (ie, from brand name to generic,
from generic to brand name or from generic to another
generic). The changes in dose and dosage form were
not accounted for during switching. Data on baseline
characteristics, including demographics, cardiovascular
risk factors and receipt of more than one cardiovascular
medication at the date of enrolment, were collected.
The data on drug prescriptions and hospitalisations that
occurred during the 12 months preceding the date of
enrolment were analysed (characterisation period). The
medication adherence in the year before the index date
was also analysed. Adherence to therapy was determined
by calculating the proportion of days covered according
to the method used by Catalan and LeLorier.23
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Only patients with at least one prescription of the index
drug in the previous 12 months were included (to capture
patients who could have made a change in therapy) and
with at least two prescriptions at follow-up (to include
patients with continuity of treatment). Patients treated
with ﬁxed combinations of the molecules under con-
sideration (ramipril and diuretics (ATC code: C09BA05),
perindopril and amlodipine (ATC code: C09BB04), rami-
pril and felodipine (ATC code: C09BB05), olmesartan
and amlodipine (ATC code: C09DB02), simvastatin and
ezetimibe (ATC code: C10BA02)) were excluded.
Patients transferred to another LHU during the
follow-up period were excluded from the analysis.
Study population
Cardiovascular risk
Patients were classiﬁed as being at high cardiovascular
risk if they had cardiovascular treatment or hospitalisa-
tion for diabetes. For each patient, hospitalisations
related to diabetes were identiﬁed by the ICD-9-CM code:
250 (primary discharge reasons); and/or cardiovascular
risk factors (previous hospitalisation for ischaemic heart
disease (acute myocardial infarction (ICD-9-CM: 410)
acute cardiac ischaemia (ICD-9-CM: 411), old myocardial
infarction (ICD-9-CM: 412), angina pectoris (ICD-9-CM:
413), chronic cardiac ischaemia (ICD-9-CM: 414));
heart failure (ICD-9-CM: 428); cerebral haemorrhage
(ICD-9-CM: 431); cerebral artery occlusion (ICD-9-CM:
434); transient cerebral ischaemia (ICD-9-CM: 435); cere-
bral circulatory disorders (ICD-9-CM: 436); atheroscler-
osis (ICD-9-CM: 440); other peripheral vascular disease
(ICD-9-CM: 443); chronic renal failure (ICD-9-CM: 585);
coronary angioplasty (ICD-9-CM procedure: 0066, 360));
and/or the presence of at least two prescriptions of anti-
diabetic drugs (ATC code: A10). All other patients were
classiﬁed as being at moderate cardiovascular risk.
Drug treatments
Patients were also characterised by the strategy of treat-
ment at baseline with lipid-lowering drugs (ATC code:
C10) and antihypertensive drugs (ATC codes: C02, C03,
C07, C08, C09).
Data analysis at follow-up
During the follow-up period, the discontinuation or
the ﬁrst substitution of therapy was identiﬁed.
Discontinuation of therapy was deﬁned as the absence
of prescriptions of the same therapeutic class (ATC
group) as the index molecule in the last quarter of
observation. A substitution of therapy was deﬁned as a
change to a different active substance of the same thera-
peutic class (ATC group) (ie, switching from simvastatin
to a different statin). A switch among different products
of the same active substance was identiﬁed by INN.
Statistical analysis
Continuous variables were reported as mean±SD and
compared using Student’s t-test; categorical variables
were reported as absolute numbers and percentages and
compared using the χ2 test.
Discontinuations of therapy and substitution with
another molecule of the same class were analysed by multi-
variate analysis using Cox proportional hazards models;
covariates considered in the models were: age, male sex,
high cardiovascular risk, cardiovascular treatments,
change of formulation in the period of characterisation.
The analysis of Schoenfeld residuals (scaled and
unscaled) was conducted to assess the proportionality of
risk.
p Values<0.05 were considered statistically signiﬁcant.
All analyses were performed using STATAV.12.0 SE.
RESULTS
Simvastatin
A total of 38 183 patients treated with simvastatin, 17 642
male (46%), mean age 68.3±10.7 years, were included in
the analysis. A total of 9392 (25%) patients were classi-
ﬁed as being at high cardiovascular risk, while 30 467
(80%) received concomitant cardiovascular treatments
(table 1).
Switches among different products occurred in 39%
of patients treated with simvastatin. Switcher patients
were mainly men with high cardiovascular risk; this
cohort of patients was slightly younger than that of non-
switcher patients, but the difference was statistically sig-
niﬁcant. With regard to switchers, a little over half
carried out one switch only during the characterisation
period, with 8% having four switches or more (table 2).
Among patients enrolled, the non-switching and switch-
ing groups showed a similar percentage of adherence
during the characterisation period (34.2% vs 33.5%
(p=0.133), respectively).
In the follow-up period, 4232 (11%) patients under-
took a therapy substitution with another molecule; a sig-
niﬁcantly lower percentage of substitution was observed
in the group that did not switch to a different product
of the same active substance (table 3).
In the same period, 8153 (21%) patients discontinued
treatment; a signiﬁcantly lower percentage of discontinu-
ation was observed for non-switching patients (table 3).
These ﬁndings were partially conﬁrmed by multivariate
analysis (table 4): the group that switched to a different
product of the same active substance showed a higher
probability of discontinuation (HR=1.087, 95% CI 1.040
to 1.136, p<0.001) and a higher, but not signiﬁcant,
probability of substitution of therapy (HR=1.059, 95% CI
0.996 to 1.126, p=0.068).
Ramipril
A total of 32 111 patients treated with ramipril, 18 493
male (58%), mean age 66.9±12.8 years, were included in
the analysis. Of these, 6898 (21%) patients were classi-
ﬁed as being at high cardiovascular risk, while 25 261
(79%) were receiving additional cardiovascular treat-
ments (table 1). Switches among different products
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occurred in 29% of patients treated with ramipril.
Switcher patients were mainly men and the difference
was statistically signiﬁcant. The switching group showed
a higher percentage of adherence than the non-
switching group during the characterisation period
(48.9% vs 46.6% (p=0.001), respectively).
With regard to switchers, again, a little over half (55%)
carried out one switch only, during the characterisation
period, and few (6%) had four switches or more (table 2).
In the follow-up period, 2496 (8%) patients undertook a
therapy substitution to another molecule; no trend
towards a lower percentage of substitution was observed in
the group that did not switch to a different product of the
same active substance (table 3). In the same period, 5677
(18%) patients discontinued treatment, with a signiﬁcant
difference in favour of patients not switching to a different
product of the same active substance (table 3). These ﬁnd-
ings were conﬁrmed by multivariate analysis (table 4):
there was essentially no difference between groups in
terms of probability of substitution (HR=0.973, 95% CI
0.892 to 1.062, p=0.540), while the non-switching group
showed a signiﬁcantly lower probability of discontinuation
of therapy (HR=1.163, 95% CI 1.100 to 1.230, p<0.001).
Amlodipine
A total of 37 467 patients treated with amlodipine, 20 339
male (54%), mean age 68.2±11.7 years, were included in
the analysis. Of these, 7126 (19%) patients were classiﬁed
as being at high cardiovascular risk, while 33 381 (89%)
were receiving additional cardiovascular treatments
(table 1). Switches among different products occurred in
28% of patients treated with amlodipine. Switcher patients
were mainly men with high cardiovascular risk; the differ-
ence was statistically signiﬁcant. Among patients enrolled,
switcher patients showed a lower percentage of adherence
during the characterisation period than non-switcher
patients (42.2% vs 43.8% (p=0.007), respectively). With
regard to switchers, just over half (54%) carried out one
switch only during the characterisation period and 7%
had four switches or more (table 2). In the follow-up
period, 1369 (4%) patients undertook a therapy substitu-
tion to another molecule; a signiﬁcantly lower percentage
of substitution was observed in the group that did not
switch to a different product of the same active substance
(table 3). In the same period, 8707 (23%) patients discon-
tinued treatment; a signiﬁcantly lower probability of dis-
continuation was observed for patients not switching to
another product of the same active substance (table 3).
These ﬁndings were conﬁrmed by multivariate analysis
(table 4): the switcher group showed a higher probability
of discontinuation (HR=1.124, 95% CI 1.074 to 1.177,
p<0.001) and substitution of therapy (HR=1.179, 95% CI
1.043 to 1.333, p=0.008).
DISCUSSION
In accordance with previous studies,24–28 this retrospect-
ive analysis in a ‘real-world’ setting shows that age,
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gender, cardiovascular risk and more than one cardio-
vascular medication on the date of enrolment could play
a role in the discontinuation of therapy. A number of
factors may interact to affect adherence to therapies for
chronic conditions. These have been categorised by the
WHO as social and economic-related factors, health
system/healthcare team-related factors, condition-related
factors and patient-related factors.15 Since poor adher-
ence has a signiﬁcant negative impact on health out-
comes and healthcare costs, and imposes a substantial
burden on patients and health systems, ‘increasing the
effectiveness of adherence interventions may have a far
greater impact on the health of the population than any
improvement in speciﬁc medical treatments’.29
The data of this study also show that, for the same
active substance, a change of product (regardless of
whether it is a brand name or generic drug) increases
the risk of discontinuation of therapy and of substitution
with another molecule of the same class. Our ﬁndings
were conﬁrmed by multivariate analysis, where the
switcher group showed a higher probability of discon-
tinuation and probability of substitution for amlodipine
and simvastatin users. Instead, among ramipril users,
there was essentially no difference between groups in
terms of probability of substitution while a higher prob-
ability of discontinuation was conﬁrmed by multivariate
analysis.
Our ﬁndings are comparable with those reported by
Ghate et al,30 who found that switching among warfarin
formulations, including substituting a generic for
another generic, might expose patients with atrial ﬁbril-
lation to a higher risk of thrombotic and bleeding
events than those remaining on the same formulation.
There is a lot of published evidence about switching
from branded to generic medicines, speciﬁcally regard-
ing the role of prescribers and pharmacists in the oppor-
tunity for generic drug use and generic substitution, as
well as concerning the acceptance by patients of generic
substitution by health providers.31 32 According to
Italian law (Patent Law and the Health Law Regulations
in Italy. Decree 95/2012), all pharmacists in Italy are
required to offer patients the opportunity to substitute a
prescribed non-generic, interchangeable medicinal
product with a less expensive generic alternative, unless
the prescriber states speciﬁcally that the prescription is
non-substitutable. At the same time, the patient can
decline the substitution of a medicinal product.
However, a previous study exploring the effect of
generic substitution showed that physician-induced
switching from brand name to generic ramipril does not
negatively affect the reﬁll compliance of patients.16
In contrast, at present only a few studies have esti-
mated the frequency and effects of substitution between
different products of the same active substance in a clin-
ical practice setting. Previous analyses suggest that
patients switching statin therapy showed signiﬁcantly
poorer compliance and higher risk of death or major
cardiovascular events when compared with controls who
did not switch.33–35
Moreover, as observed in other studies, this study indi-
cates that age, sex and the presence of cardiovascular
risk were associated signiﬁcantly with the presence of
switching to a different product of the same active
substance.36
In addition, our results are also comparable with
others that focused on different chronic therapies, such
as a recent study by Kesselheim et al showing that
changes in pill colours and shapes increased the risk of
non-adherence among patients with epilepsis.37 The pos-
sibility that variation in packaging and pill appearance,
as well as in the shape and colour of either box or
tablet, may affect adherence is a reason for concern.
However, we cannot exclude the possibility that other
potential determinants can play a key role in a reduction
of patients’ adherence. Observational studies38–40 have
demonstrated a relationship between age, gender, car-
diovascular risk factors, more than one cardiovascular
medication and a suboptimal adherence to therapy; our
ﬁndings are in agreement with these previous analyses.
The majority of the published studies showed that age
was related to adherence, although a few researchers
found age not to be a factor causing non-adherence.
New evidence suggests that older age is not related to
poorer medication adherence to cardiovascular medica-
tion. A recent systematic search of the bibliographic
database MEDLINE and all Cochrane databases, analys-
ing the relationship between age and medication adher-
ence in adult patients with chronic heart failure (CHF),
showed that older age alone is not related to poorer
medication adherence compared with younger patients
Table 2 Annual frequency of switches
Simvastatin Ramipril Amlodipine
Switches (N) Patients (%) Switches (N) Patients (%) Switches (N) Patients (%)
1 7842 (52) 1 5112 (55) 1 5710 (54)
2 4062 (27) 2 2501 (27) 2 2871 (27)
3 1917 (13) 3 1116 (12) 3 1300 (12)
4 805 (5) 4 413 (4) 4 563 (5)
≥5 377 (3) ≥5 170 (2) ≥5 200 (2)
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with CHF.41 Our study does not support this concern.
Several studies also attempted to hypothesise plausible
reasons for poorer compliance among elderly patients.
Elderly patients may have problems with vision, hearing
and memory. In addition, they may have more difﬁcul-
ties in following therapy instructions due to cognitive
impairment or other physical difﬁculties, such as having
problems in swallowing tablets, opening drug containers,
handling small tablets, distinguishing colours or identify-
ing markings on drugs.42
However, the underlying reasons for poor adherence
are not fully understood, and there may be many
reasons behind these behaviours, some of which relate
to the perceptions that physicians, pharmacists and
patients may have of drugs and therapies. Nevertheless,
the clinical consequences that may result from these per-
ceptions are important and should be considered.
Establishing better physician–patient communication,
improving patient education and maintaining regular
follow-up and review of patients’ progress may be as
important as other factors in encouraging adherence
and lead to improved health outcomes and enhanced
patient safety.15 This includes addressing patients’ per-
ceptions about the medications they are prescribed and
understanding that they may ﬁnd routine changes in the
name and appearance of long-term medications
challenging.
Our analysis has several limitations inherent to any
observational study. First, the study was performed using
the administrative databases, and the reasons for switch,
non-adherence or discontinuation of treatment in the
patients were not retrievable from the data set. Also, no
information on the role of the prescribers regarding
switching within the same class or the role of the coun-
selling pharmacist when substituting and dispensing
drug packages was available to us. A second limitation is
a relatively limited sample size. Although in our study we
used the healthcare databases of Lombardy, Lazio and
Campania, three Italian Regions localised from north to
south of Italy, including data for a total population of
about 2 million and considering that we have focused
our analysis among users of simvastatin, ramipril and
amlodipine, larger studies are needed to conﬁrm and to
enhance the generalisability of the ﬁndings, and in dif-
ferent populations. Third, our study did not include an
outcome analysis and the evaluation of the clinical con-
sequences of switching was beyond the scope of this
work.
Despite these limitations, our study indicates that in a
‘real-world’ setting, changes among different products of
the same active substance, including switching brand
name to generic, generic to another generic and
generic to brand name, are quite common among
patients with CVD. Our ﬁndings suggest that switching
to a different product of the same off-patent active sub-
stance, brand name or generic may expose patients to a
higher risk of therapy discontinuation or substitution
than continuing treatment with the same product.
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